Salt-inducible kinases as druggable targets for immunotherapy of ovarian cancer

Nature Immunology, Published online: 21 May 2026; doi:10.1038/s41590-026-02513-7 Malignant ascites strongly inhibits T cell anti-tumor responses in patients with high-grade serous ovarian cancer (HGSOC). Using an all-human high-throughput drug repurposing screen, we identified salt-inducible kinases (SIKs) as negative regulators of T cell function in ascites. Pharmacological inhibition or genetic depletion of SIK2 and SIK3 in T cells strongly upregulates anti-tumor immunity and improves survival